SUPN
Supernus Pharmaceuticals Stock Analysis
AI Rating
- Quality6/10
- Growth↓ 0/10
- Value↓ 1/10
SUPN Growth
- Revenue Y/Y↑ 12.72%
- EPS Y/Y↓ -145.13%
- FCF Y/Y↓ -49.65%
SUPN Profitability
- Gross margin ↑ 89.40%
- EPS margin↓ -3.70%
- ROIC 5Y↓ 8.20%
SUPN Risk
- Debt / Equity↓ 0.0
- Debt / FCF↓ 0.0
- Interest coverage↓ NA
Supernus Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.